These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 30170223)

  • 1. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Cao YX; Liu HH; Sun D; Jin JL; Xu RX; Guo YL; Wu NQ; Zhu CG; Li S; Zhang Y; Sun J; Li JJ
    Atherosclerosis; 2018 Oct; 277():7-14. PubMed ID: 30170223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
    Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia.
    Sun D; Zhou BY; Zhao X; Li S; Zhu CG; Guo YL; Gao Y; Wu NQ; Liu G; Dong Q; Li JJ
    J Clin Lab Anal; 2018 Sep; 32(7):e22442. PubMed ID: 29603377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque.
    Ooi EM; Ellis KL; Barrett PHR; Watts GF; Hung J; Beilby JP; Thompson PL; Stobie P; McQuillan BM
    Atherosclerosis; 2018 Aug; 275():232-238. PubMed ID: 29960898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
    Alonso R; Mata P; Muñiz O; Fuentes-Jimenez F; Díaz JL; Zambón D; Tomás M; Martin C; Moyon T; Croyal M; Thedrez A; Lambert G
    Atherosclerosis; 2016 Nov; 254():249-253. PubMed ID: 27594539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender.
    Mattina A; Giammanco A; Giral P; Rosenbaum D; Carrié A; Cluzel P; Redheuil A; Bittar R; Béliard S; Noto D; Quartarone A; Averna M; Bruckert É; Gallo A
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1068-1076. PubMed ID: 31378630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
    Li S; Wu NQ; Zhu CG; Zhang Y; Guo YL; Gao Y; Li XL; Qing P; Cui CJ; Xu RX; Sun J; Liu G; Dong Q; Li JJ
    Atherosclerosis; 2017 May; 260():67-74. PubMed ID: 28351002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y; Harada-Shiba M; Nakao K; Nakashima T; Kawakami S; Fujino M; Kanaya T; Nagai T; Tahara Y; Asaumi Y; Hori M; Ogura M; Goto Y; Noguchi T; Yasuda S
    J Clin Lipidol; 2017; 11(2):413-421.e3. PubMed ID: 28502498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
    Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly.
    Croyal M; Blanchard V; Ouguerram K; Chétiveaux M; Cabioch L; Moyon T; Billon-Crossouard S; Aguesse A; Bernardeau K; Le May C; Flet L; Lambert G; Hadjadj S; Cariou B; Krempf M; Nobécourt-Dupuy E
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):819-829. PubMed ID: 32078365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children.
    Girona J; Rodríguez-Borjabad C; Ibarretxe D; Heras M; Amigo N; Feliu A; Masana L; Plana N;
    J Clin Lipidol; 2018; 12(1):211-218. PubMed ID: 29102496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography.
    Panahi Y; Ghahrodi MS; Jamshir M; Safarpour MA; Bianconi V; Pirro M; Farahani MM; Sahebkar A
    Clin Biochem; 2019 Dec; 74():12-18. PubMed ID: 31493378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia.
    Bos S; Duvekot MH; Touw-Blommesteijn AC; Verhoeven AJ; Mulder MT; Watts GF; Sijbrands EJ; Roeters van Lennep JE
    Atherosclerosis; 2015 Sep; 242(1):226-9. PubMed ID: 26222903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.
    Bos S; Duvekot MH; Ten Kate GR; Verhoeven AJ; Mulder MT; Schinkel AF; Nieman K; Watts GF; Sijbrands EJ; Roeters van Lennep JE
    Atherosclerosis; 2017 Jan; 256():62-66. PubMed ID: 28012444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia.
    Ogura M; Hori M; Harada-Shiba M
    Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):181-8. PubMed ID: 26543100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population.
    Ueshima H; Kadowaki T; Hisamatsu T; Fujiyoshi A; Miura K; Ohkubo T; Sekikawa A; Kadota A; Kadowaki S; Nakamura Y; Miyagawa N; Okamura T; Kita Y; Takashima N; Kashiwagi A; Maegawa H; Horie M; Yamamoto T; Kimura T; Kita T;
    Atherosclerosis; 2016 Mar; 246():141-7. PubMed ID: 26775119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.
    Yang SH; Li S; Zhang Y; Xu RX; Zhu CG; Guo YL; Wu NQ; Qing P; Gao Y; Cui CJ; Dong Q; Sun J; Li JJ
    J Endocrinol Invest; 2016 Aug; 39(8):875-83. PubMed ID: 26894681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.
    Cao YX; Jin JL; Sun D; Liu HH; Guo YL; Wu NQ; Xu RX; Zhu CG; Dong Q; Sun J; Li JJ
    J Transl Med; 2019 Nov; 17(1):367. PubMed ID: 31711505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.